SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of
Report (Date of earliest event reported) July 28, 1997
ALFACELL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-11088 22-2369085
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
225 Belleville Avenue Bloomfield, New Jersey 07003
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (201) 748-8082
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
Michael C. Lowe resigned as a director and President of
Alfacell Corporation (the "Registrant"). The resignation was mutually agreed
upon by Dr. Lowe and the Registrant. Strategic and daily business operations
will remain the responsibility of Kuslima Shogen, the Registrant's co-founder
and Chief Executive Officer and Gail E. Fraser, the Registrant's Chief Financial
Officer and Vice President of Finance. Pharmaceutical executives Dr. Stephen K.
Carter, formerly Senior Vice President of Bristol-Myers Squibb for worldwide
clinical research and development and Donald R. Conklin, former President of
Schering-Plough Pharmaceuticals, have recently joined the Registrant's Board of
Directors and, in addition to their board responsibilities, will be actively
advising the Registrant in the areas of product and business development.
- 2 -
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: August 12, 1997
ALFACELL CORPORATION
(Registrant)
By: /s/ GAIL E. FRASER
----------------------
GAIL E. FRASER
Chief Financial Officer
and Vice President of
Finance
